利妥昔单抗联合CHOP方案与单用CHOP方案治疗弥漫性大B细胞淋巴瘤的临床对比研究  

Clinical Comparative Study for Rituximab Combined with CHOP Scheme and CHOP Scheme Alone in Treating Diffuse large B Cell Lymphoma

作　　者：邢玉 

机构地区：[1]河南省许昌市中心医院,461000

出　　处：《中国全科医学》2017年第A01期94-95,共2页Chinese General Practice

摘　　要：目的研究弥漫性大B细胞淋巴瘤(DLBCL)给予利妥昔单抗联合CHOP方案治疗的临床疗效。方法从许昌市中心医院于2012年9月—2016年6月就诊的DLBCL患者中选取68例;随机分为常规组32例,研究组36例;常规组行CHOP方案治疗,研究组行利妥昔单抗联合CHOP方案治疗,对比两组患者治疗后疗效及毒副作用的情况。结果研究组患者治疗有效率高于常规组,差异有统计学意义(P<0.05);研究组便秘、转氨酶升高、恶心呕吐的发生率与常规组比较,差异无统计学意义(P>0.05);研究组白细胞计数降低、贫血、发热、感染的发生率低于常规组,差异有统计学意义(P<0.05)。结论给予利妥昔单抗联合CHOP方案治疗DLBCL可有效提高疗效,且毒副作用未增加,安全可靠。Objective To study the clinical efficacy of rituximab combined with CHOP in treating diffuse large B cell lymphoma( DLBCL). Methods 68 cases of patients with DLBCL treated in Xuchang Central Hospital from September 2012 to June 2016 were selected and randomly divided into routine group 32 cases and study group 36 cases. Routine group were provided with conventional CHO treatment,whileresearch group were provided with rituximab combined with CHOP. Patients in two groups were compared withefficacy and adverse reaction after treatment. Results Overall treatment efficacy of patients in research group was 88. 89%,which was obviously higher than that ofroutine group with 59. 38%,having statistical significance( P < 0. 05);the occurrence rate of adverse reactions such as decrease of wbc,anemia,fever and infection of research group were obviously lower than those of routine group,having statistical significance( P < 0. 05); there was no obvious difference in occurrence rate of adverse reactions such as constipation,transaminase elevation and nausea and vomiting between patients in two groups,with statistical significance( P > 0. 05). Conclusion Rituximab combined with CHOP scheme works excellently in treating diffuse large B cell lymphoma without adding adverse reactions and it is safe.

关 键 词：淋巴瘤 大B细胞 弥漫性 抗肿瘤联合化疗方案 利妥昔单抗 

分 类 号：R733.41[医药卫生—肿瘤]